News
- November 23, 2011 | from Medicines Sans Frontiers Access to HIV treatment must speed up to match political promises The latest UNAIDS treatment numbers show progress, but funding crunch is major threat.
- November 09, 2011 | from JAMA Conflict of Interest Disclosure in Early Education of Medical Students Medical education has embraced the transparency movement by shining the light of disclosure on physician-industry interactions. However, disclosure has not yet trickled down to the very start of medical education. Are first- and second-year students justified in expecting conflicts of interest disclosure in their education?
- November 09, 2011 | from Postscript Where's the Sunshine? October is when HHS was supposed to issue rules implementing the Physician Payment Sunshine provisions of health reform. Senators Grassley and Kohl have been urging HHS to issue regulations as quickly as possible but they have not been answered.
- October 27, 2011 | from AMSA Is On The Move... Literally! We are delighted to announce that AMSA and the AMSA Foundation are moving! At the end of November, the new headquarters will be in a state-of-the-art facility located just a few miles from Dulles International Airport, in Sterling, VA.
- June 26, 2011 | from JAMA Report Calls for US Funding to Speed Global Health Research and Innovation A coalition of 30 nonprofit health organizations promoting the development of drugs, vaccines, and other health-related products designed for use in the developing world is calling on US policy makers and regulators to accelerate scientific innovation and streamline the approval process for safe and affordable new medical products that can be used worldwide.
- June 26, 2011 | from Pharmalot Teaching Med Students About Industry Influence For the past few years, one of the more contentious controversies has been the close financial ties between drugmakers and some doctors. But why have some docs embraced the pharmaceutical industry? Were their attitudes formed early in their careers? If so, would there be virtue in educating medical students and residents about the downside to industry interactions?
- June 10, 2011 | from UNAIDS Bold new AIDS targets set by world leaders for 2015 Unprecedented global participation at UN General Assembly High Level Meeting on AIDS leads to new commitments, targets, and momentum in the AIDS response
- June 10, 2011 | from Infographic of the Day Infographic Of The Day: The Dirty Ties Between Docs And Drug Makers Amid all the debate about our rising health care costs, one thing you almost never hear about is rising drug costs. Think about it: You hear plenty about emergency rooms and chronic care, but nothing about drug prices, which are the main interaction most of us have with the medical industry. And that's totally ridiculous: No wonder health care costs are rising so fast, when your doctor prescribes you a $100-a-month drug that could be replaced by a generic, but whose cost neither you nor your doctor is aware of, thanks to the mediating presence of an insurance company.
- May 31, 2011 | from Pharma Times Online Banning DTC ads could harm patients, says US CBO A ban on direct-to-consumer advertising (DTCA) of new medicines during the first two years after regulatory approval could prove harmful to patients, the US Congressional Budget Office (CBO) has warned.
- May 30, 2011 | from Toronto Star Global Voices: Dying for life-saving drugs We build schools in Kenyan villages where teachers die, but their students refuse to name the cause because of its potent stigma, even as coffins are lowered into graves. We've seen husbands, mothers, and then their children, wither away from a mysterious illness rather than be ostracized with a diagnosis. In North America, access to treatment makes it possible for people with HIV/AIDS to lead relatively comfortable lives. In developing countries, where antiretroviral drugs (ARVs) are prohibitively expensive, AIDS is a curse. There's still no cure, but Canada has a chance to save potentially millions of lives with a single legislation. Bill C-393 would reform Canada’s Access to Medicines Regime, a system so flawed it's only been used to ship a single drug to Rwanda since it was first introduced six years ago.
